通过对线粒体的干扰来准急性髓性白血病干细胞
Anagha Inguva Sheth1, Mark J Althoff1, Hunter Tolison1
1Division of Hematology, University of Colorado School of Medicine, Aurora, Colorado.
Cancer discovery
|May 24, 2024
概括
向线粒体摄取消除了抗venetoclax的急性髓性白血病干细胞 (LSCs). 这项研究揭示了LSC中独特的信号,通过抑制氧化酸化 (OXPHOS) 来提供一种新的抗药性策略.
科学领域:
- 癌症生物学 癌症生物学
- 细胞代谢 细胞代谢
- 血液学 血液学 血液学
背景情况:
- 急性髓性白血病干细胞 (LSCs) 需要氧化酸化 (OXPHOS) 才能生存.
- 抗BCL-2抑制剂venetoclax通过抑制OXPHOS向LSC,但药物耐药性是一个重大的临床挑战.
研究的目的:
- 研究 mitochondrial 特性 影响 LSC 中的 venetoclax 响应性.
- 确定新的治疗策略,以克服AML中的venetoclax耐药性.
主要方法:
- 线粒体利用在药物响应性与非响应性LSC中的比较分析.
- 基因和药理学抑制线粒体单载体的抑制.
- 在干预后评估OXPHOS水平和LSC根除.
主要成果:
- 威尼托克拉克斯耐药的LSCs表现出活性OXPHOS状态,其中线粒体水平升高.
- 抑制线粒体吸收有效地减少了OXPHOS.
- 向线粒体单载体的向导致了对venetoclax耐药的LSCs的根除.
结论:
- 线粒体利用率的增加是venetoclax耐药LSCs的一个关键代谢漏洞.
- 准线粒体摄取量是一个有希望的治疗策略,用于管理AML中的venetoclax耐药性.
- 信号传递在LSC生存和药物耐药性方面发挥着至关重要的作用.
更多相关视频
09:44Flow Cytometric Analysis of Mitochondrial Reactive Oxygen Species in Murine Hematopoietic Stem and Progenitor Cells and MLL-AF9 Driven Leukemia
Published on: September 5, 2019
7.3K
07:58An Automated Differential Nuclear Staining Assay for Accurate Determination of Mitocan Cytotoxicity
Published on: May 12, 2020
6.9K
相关概念视频
Electron Transport Chain: Complex I and II
13.0K
The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
ROS generation is regulated and maintained at moderate levels necessary...
13.0K
Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K
Cancer Stem Cells and Tumor Maintenance
4.9K
Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
4.9K
